Scarica l'app Stockscreener
3.70
1.65%
0.06
Precedente Chiudi:
$3.64
Aprire:
$3.66
Volume 24 ore:
1.90M
Relative Volume:
1.44
Capitalizzazione di mercato:
$282.61M
Reddito:
$80.00M
Utile/perdita netta:
$-76.12M
Rapporto P/E:
-3.2272
EPS:
-1.1465
Flusso di cassa netto:
$-63.88M
1 W Prestazione:
-0.54%
1M Prestazione:
-1.07%
6M Prestazione:
-52.07%
1 anno Prestazione:
-61.66%
Intervallo 1D:
$3.63
$3.735
Intervallo di 1 settimana:
$3.63
$3.735
Portata 52W:
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Nome
Fulcrum Therapeutics Inc
Settore
Industria
Telefono
617-651-8851
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.70 | 282.61M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-03 | Downgrade | JP Morgan | Overweight → Underweight |
| 2026-06-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2026-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-06-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2026-06-02 | Downgrade | Stifel | Buy → Hold |
| 2026-06-02 | Downgrade | Truist | Buy → Hold |
| 2026-01-12 | Iniziato | JP Morgan | Overweight |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-07-29 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Downgrade | Stifel | Buy → Hold |
| 2024-09-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-09-25 | Iniziato | Goldman | Neutral |
| 2023-08-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Aggiornamento | Stifel | Hold → Buy |
| 2023-05-04 | Downgrade | Goldman | Buy → Neutral |
| 2023-03-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Downgrade | Stifel | Buy → Hold |
| 2023-02-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Iniziato | Goldman | Buy |
| 2022-03-08 | Iniziato | Oppenheimer | Outperform |
| 2022-03-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2020-10-16 | Iniziato | Piper Sandler | Overweight |
| 2020-08-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-12 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Fulcrum Therapeutics Stock Price Forecast. Should You Buy FULC? - StockInvest.us
FULC 8-K & SEC FilingsYahoo Finance - Yahoo! Finance Canada
A roughly 5% fully diluted stake and a pre-merger cash dividend are expected for Fulcrum (FULC) holders. - Stock Titan
Halper Sadeh LLC is Investigating Whether CSR, FULC, WEAV, PSNL are Obtaining Fair Deals for their Shareholders - globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - Supply Chain Digital Magazine
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - GlobeNewswire Inc.
Fulcrum Therapeutics (FULC) Edges Higher to $3.79 as Shares Test Upper RangeJelly Roll Trade - dars.gov.et
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Investigation Into Possible Securities Law Violations - NewMediaWire
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inv - The National Law Review
Halper Sadeh LLC is Investigating Whether CSR, EFSI, FULC, TECH are Obtaining Fair Deals for their Shareholders - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ... - pmg-ky3.com
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to an Ongoing Investigation Into Possible Securities Law Violations - NewMediaWire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - globenewswire.com
Halper Sadeh LLC is Investigating Whether FULC, ATKR, FNWD are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Halper Sadeh LLC is Investigating Whether FULC, ATKR, FNWD are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inves - The National Law Review
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Collapse - kalkine.ca
TOIIW Warrant Holds Flat at $0.05 as The Oncology Institute Awaits CatalystsBuy Signal Reports - careplusvn.com
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law Violations - The National Law Review
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law Violations - NewMediaWire
Greg Tourangeau, Former Fulcrum Therapeutics Officer, to Sell 14,062 Shares Worth $54,420 - kalkinemedia.com
Kaplan Fox Launches Securities Investigation Into Fulcrum Therapeutics After 51% Stock Collapse - kalkine.ca
Former Fulcrum Therapeutics (FULC) officer moves to sell about $54K in stock - Stock Titan
Fulcrum (NASDAQ: FULC) plans special cash dividend ahead of Slate Medicines merger - Stock Titan
Kaplan Fox Initiates Securities Probe Into Fulcrum Therapeutics Following 51% Stock Plunge - Kalkine Media
Fulcrum Therapeutics Inc. (FULC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - The Globe and Mail
Fulcrum Therapeutics Faces Securities Law Investigation After Pociredir Programme Discontinuation Triggers 51% Stock Drop - kalkine.ca
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough? - Yahoo Finance
Fulcrum (FULC) Close: Ends Up by 0.26% at $3.84; Chart View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionVolatility Smile - vinanet.vn
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corpo - mykxlg.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Sahm
Fulcrum Therapeutics Stock Drops 51% After Pociredir Discontinuation Triggers Securities Investigation - kalkine.ca
Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders? - Morningstar
Fulcrum (FULC) Stock: Falls 0.52% to $3.83 at the Close; Chart View: Support at $3.64 and Resistance at $4.02 Frame the Range in the Latest SessionAnalyst Upgrade Stocks - vinanet.vn
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Morningstar
Fulcrum (FULC) Quarter in Focus: The Available Earnings Metric Delivers a Beat in the Current Update; Market Response: Shares Finish 1.03% Higher on the DayEarnings Revision Report - vinanet.vn
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc.FULC - Business Wire
Fulcrum Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Slate Medicines to Merge With Fulcrum Therapeutics - Cooley
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations - FinancialContent
Truist Financial Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating - Moomoo
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines - Sahm
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - Sahm
Latham Advises Frazier Life Sciences on Private Placement Financing in Connection With Fulcrum Therapeutics and Slate Medicines Merger - Legal Desire
Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger - Latham & Watkins LLP
Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fulcrum Therapeutics Inc Azioni (FULC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | 10% Owner |
Jul 17 '26 |
Buy |
3.52 |
50,945 |
179,326 |
7,080,945 |
| TANG KEVIN | 10% Owner |
Jul 16 '26 |
Buy |
3.56 |
116,671 |
415,349 |
7,030,000 |
| TANG KEVIN | 10% Owner |
Jul 15 '26 |
Buy |
3.56 |
107,377 |
382,262 |
6,913,329 |
| TANG KEVIN | 10% Owner |
Jul 14 '26 |
Buy |
3.57 |
129,603 |
462,906 |
6,805,952 |
| TANG KEVIN | 10% Owner |
Jul 13 '26 |
Buy |
3.54 |
12,966 |
45,900 |
6,676,349 |
| Ezekowitz Alan | Director |
Jun 26 '26 |
Sale |
3.65 |
18,000 |
65,614 |
10,927 |
| ALAN EZEKOWITZ | Director |
Jun 26 '26 |
Proposed Sale |
3.61 |
18,000 |
64,980 |
0 |
| Gould Robert J | Director |
Feb 02 '26 |
Sale |
10.72 |
15,000 |
160,857 |
454,864 |
| Gould Robert J | Director |
Jan 02 '26 |
Sale |
11.87 |
15,000 |
178,089 |
469,864 |
| Oltmans Curtis Gale | Chief Legal Officer |
Dec 15 '25 |
Sale |
12.92 |
3,452 |
44,600 |
10,252 |
5.91%
2.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):